D. Western Therapeutics Institute Beheer

Beheer criteriumcontroles 1/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Yuichi Hidaka

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	15.9yrs
Eigendom CEO	7.7%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	10.6yrs

Recente managementupdates

Recent updates

Is D. Western Therapeutics Institute (TSE:4576) Using Debt Sensibly?

May 23

CEO

Yuichi Hidaka (51 yo)

15.9yrs

Tenure

Mr. Yuichi Hidaka has been President of D.Western Therapeutics Institute, Inc.(DWTI) since December 2008 and serves as its Chief Executive Officer. Mr. Hidaka serves as a Director at Actual Eyes Inc. He se...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yuichi Hidaka	President	15.9yrs	geen gegevens	7.69% ¥ 201.6m
Sayako Matsubara	CFO & Director	1.7yrs	geen gegevens	0.015% ¥ 386.5k
Yoshiyuki Yamakawa	Independent Outside Director	14.7yrs	geen gegevens	0.047% ¥ 1.2m
Eisaku Nakamura	Independent Outside Director	6.6yrs	geen gegevens	0.00026% ¥ 6.8k
Masaaki Suzuki	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Tasuku Honjyo	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Masato Shibuya	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Arata Uemura	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Anthony Means	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Walter Chazin	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Yasuhiko Ito	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Yasumi Uchida	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

10.6yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren bestuur: 4576's board of directors are seasoned and experienced ( 10.6 years average tenure).

D. Western Therapeutics Institute Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 27, 2024

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 30, 2023

Insufficient new directors

Insufficient new directors

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 29, 2022

Recent updates

D. Western Therapeutics Institute, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Second quarter 2024 earnings released: JP¥6.18 loss per share (vs JP¥4.73 loss in 2Q 2023)

New major risk - Share price stability

New minor risk - Shareholder dilution

Is D. Western Therapeutics Institute (TSE:4576) Using Debt Sensibly?

First quarter 2024 earnings released: JP¥9.96 loss per share (vs JP¥3.11 loss in 1Q 2023)

New minor risk - Shareholder dilution

Insufficient new directors

D. Western Therapeutics Institute, Inc. to Report Q1, 2024 Results on May 13, 2024

D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024

Full year 2023 earnings released: JP¥25.55 loss per share (vs JP¥14.47 loss in FY 2022)

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 27, 2024

D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: JP¥6.11 loss per share (vs JP¥3.94 loss in 3Q 2022)

New minor risk - Share price stability

D. Western Therapeutics Institute, Inc. to Report Q3, 2023 Results on Nov 10, 2023

Second quarter 2023 earnings released: JP¥4.73 loss per share (vs JP¥3.03 loss in 2Q 2022)

D. Western Therapeutics Institute, Inc. to Report Q2, 2023 Results on Aug 10, 2023

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024

First quarter 2023 earnings released: JP¥3.11 loss per share (vs JP¥0.71 loss in 1Q 2022)

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023

Full year 2022 earnings released: JP¥14.47 loss per share (vs JP¥5.05 loss in FY 2021)

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 30, 2023

D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023

Insufficient new directors

Third quarter 2022 earnings released: JP¥3.94 loss per share (vs JP¥0.65 loss in 3Q 2021)

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

D. Western Therapeutics Institute, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: JP¥3.03 loss per share (vs JP¥1.40 loss in 2Q 2021)

D. Western Therapeutics Institute, Inc. announced that it has received ¥901.216203 million in funding from Whiz Partners Inc.

D. Western Therapeutics Institute, Inc. to Report Q2, 2022 Results on Aug 09, 2022

D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Insufficient new directors

D. Western Therapeutics Institute, Inc. to Report Q1, 2022 Results on May 12, 2022

D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 29, 2022

D. Western Therapeutics Institute, Inc. to Report Q1, 2021 Results on May 13, 2021

D. Western Therapeutics Institute, Inc. to Report Q3, 2020 Results on Nov 12, 2020

D. Western Therapeutics Institute, Inc. announced that it has received ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm

D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm

CEO

Tenure

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd